Inventor · disambiguated record
Yingxia Sang
Also filed as: SANG YINGXIA
9 granted patents·4 pending applications·7 citations·filing 2012–2023
79Inventor score
Top patents by PatentIndex Score
13 records- 0177US11999719B2Solid form of compoundINXMED NANJING CO LTD·Filed 2023·Granted Jun 4, 2024·0 cites·12 claims
- 0277US9815841B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Nov 14, 2017·2 cites·13 claims
- 0372US10618901B2LRRK2 inhibitors for the treatment of Parkinson's diseaseGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Apr 14, 2020·1 cites·21 claims
- 0470US11034696B2Compounds for inhibiting LRRK2 kinase activityGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Jun 15, 2021·1 cites·18 claims
- 0568US8975400B22,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitorsWAN ZEHONG·Filed 2012·Granted Mar 10, 2015·2 cites·14 claims
- 0667US10975081B2Substituted fused pyrazole compounds and their use as LRRK2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Apr 13, 2021·1 cites·18 claims
- 0761US2023278985A1Solid form of compoundINXMED NANJING CO LTD·Filed 2021·Application pending·0 cites
- 0852US9051325B2Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2GLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jun 9, 2015·0 cites·6 claims
- 0945US9708330B22,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jul 18, 2017·0 cites·8 claims
- 1040US2020002323A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 1139US10858367B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Dec 8, 2020·0 cites·18 claims
- 1238US2021130339A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 1337US2019389850A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →